SCO­TUS de­clines to re­view En­brel biosim­i­lar case, tee­ing up 30+ years of ex­clu­siv­i­ty and $20B more for Am­gen’s block­buster

As the House Over­sight Com­mit­tee is set to grill Ab­b­Vie CEO Richard Gon­za­lez on Tues­day over tac­tics to block com­pe­ti­tion for its best-sell­ing drug of all time, an­oth­er de­ci­sion on Capi­tol Hill on Mon­day opened the door for bil­lions more in Am­gen prof­its over the next eight years.

The Supreme Court on Mon­day de­nied No­var­tis sub­sidiary San­doz’s pe­ti­tion to re­view a Fed­er­al Cir­cuit’s Ju­ly 2020 de­ci­sion con­cern­ing its biosim­i­lar Erelzi (etan­er­cept-sz­zs), which FDA ap­proved in 2016 as a biosim­i­lar to Am­gen’s En­brel (etan­er­cept). Sam­sung’s En­brel biosim­i­lar Eti­co­vo al­so won ap­proval in 2019 and re­mains side­lined.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.